FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Last updated: April 5, 2021
Sponsor: Fudan University
Overall Status: Active - Recruiting

Phase

2

Condition

Digestive System Neoplasms

Liver Cancer

Colon Cancer

Treatment

N/A

Clinical Study ID

NCT04832776
Cetu-Bev-FOLFOXIRI
  • Ages 18-75
  • All Genders

Study Summary

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ECOG perfomance 0-1
  • pathologically confirmed colorectal carcinoma, with RAS wild type
  • inital unresectable liver metastases discussed by MDT
  • prior no systemical therapy or exceed 6 months after the adjuvant chemotherapy ofprimary tumor surgery.
  • without extraheptic metastatic lesions, except for locally controlled lung metastases (RFA or SBRT)
  • adequate blood, liver and renal function
  • expected survival longer than 6 months

Exclusion

Exclusion Criteria:

  • with bleeding risk
  • interestinal obstruction or disease
  • uncontrolled hypertension and severe heart disease
  • previous severe thrombotic events
  • central nervous system metastases
  • accompanied with other malignant tumor

Study Design

Total Participants: 160
Study Start date:
April 17, 2021
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Department of Colorectal Surgery Fudan University Shanghai Cancer Center

    Shanghai, Shanghai 200032
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.